Metrics as of 10/15/2026, 11:33 AM (Berlin time), refresh in progress.
Q32 Bio Stock
Q32 Bio Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jodie Pope Morrison
- Employees
- 22
- Market cap
- $238 M
- IPO
- 28/03/2018
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary…
Q32 Bio stock: price history
1D
-0.6%
1W
+0.3%
1M
-26.6%
6M
+31.5%
YTD
+141.3%
1Y
+107.0%
2Y
-82.7%
5Y
-92.8%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~3% stronger price swings than usual
Q32 Bio stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 12/08/2026.
Ask the agents about Q32 Bio
Analyst assessment of Q32 Bio
PRICE TARGET LOW
US$14.00
CONSENSUS
US$36.50
MEDIAN
US$35.00
PRICE TARGET HIGH
US$66.00
0
STRONG BUY
4
BUY
4
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 28/07/2026
Q32 Bio stock metrics
P/E
2.87
P/B
1.07
EV/EBITDA
3.98
RETURN ON EQUITY
-8.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.05
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
42.8%
FLOAT SHARES
12,732,698
AVG. DAILY VOLUME (30D)
1,023,272
Insider transactions (SEC)
Morrison Jodie Pope
Violette Shelia M.
Kalowski Lee
Kalowski Lee
Morrison Jodie Pope
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -0.6%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Q32 Bio stock
What does Q32 Bio do?
Q32 Bio Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jodie Pope Morrison, the company employs around 22 people.
The IPO was on 28/03/2018; the stock trades on NASDAQ under the ticker QTTB.
What do analysts say about Q32 Bio stock?
8 analysts rate the stock, the consensus is Buy (as of 28/07/2026).
The average price target is US$36.50, ranging from US$14.00 to US$66.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does Q32 Bio report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Q32 Bio pay a dividend?
No, Q32 Bio currently does not pay a dividend.
Which stocks are comparable to Q32 Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Q32 Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Q32 Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.